Johnson & Johnson today announced that the U.S. Food and Drug Administration's Vaccines and Related Biological Products Advisory Committee unanimously voted to recommend Emergency Use Authorization for the Company's single-shot COVID-19 vaccine candidate for adults 18 and older, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson. The vote was based on a totality of scientific evidence provided by .
Limon: Q4 2020
Total mine production consisted of 219,428 ore tonnes at an average grade of 4.28 g/t gold. The majority of the mine production originated from the Limon Central (173,651 tonnes at an average grade of 4.51 g/t gold), the Santa Pancha underground mine (29,559 tonnes at an average grade of 3.11 g/t gold), with the remaining tonnes mined from Veta Nueva. Effective June 1, 2020, the Company considers Limon Central Phase 2 to be in commercial production and defers stripping waste material above the average life of mine waste : ore strip ratio.
Limon produced 19,006 ounces driven by an average mill grade of 5.48 g/t gold and recovery of 89.5% from 120,109 tonnes of ore milled. Gold production in Q4 2019 was 15,440 ounces, slightly lower when compared to Q4 2020, as a result of higher tonnes processed from operating for 3 months (in Q4 2020) compared to 2½ months in Q4 2019. AISC
%
In fourth quarter 2020, the company generated $109 million of revenue with attendance of 2.2 million guests, a net loss of $86 million, and an Adjusted EBITDA loss of $39 million. The net loss and Adjusted EBITDA loss include an increase in reserves of approximately $19 million. The total amount recorded reflects management’s estimate of the probable outcome of a legacy class action lawsuit. The Adjusted EBITDA calculation reflects an add-back adjustment of approximately $5 million of non-recurring costs related to the transformation plan, including $3 million of employee termination costs and $2 million of consulting costs.
The decrease in attendance was due to the temporary pandemic-related limitations on park operations at several of the company’s parks, and capacity restrictions at the parks that were open. Four parks provided drive-through or walk-through only experiences for the holiday season, and the company’s parks in Mexico were open for only a portion of the quar
LAVAL, QC, Feb. 24, 2021 /PRNewswire/ - Neptune Wellness Solutions Inc. ( Neptune or the Company ) (NASDAQ: NEPT) (TSX: NEPT), a diversified and fully integrated health and wellness company focused on natural, plant-based, sustainable and purpose-driven lifestyle brands, today announced groundbreaking research on the absorption of omega-3 fish oils, which are the basis of its exclusive product MaxSimil®. The study was published in
The Journal of Nutrition by the Oxford University Press.
MaxSimil® is a patented omega-3 fatty acid delivery technology that uses enzymes that mimic the natural human digestive system to predigest omega-3 fatty acids.
The study titled Pharmacokinetics of Supplemental Omega-3 Fatty Acids Esterified in Monoglycerides, Ethyl Esters, or Triglycerides in Adults in a Randomized Crossover Trial adds to a growing body of research on Neptune s patented MaxSimil® fish oils.